Research Project
9562138
The goal of this SBIR proposal is to develop an effective enzyme replacement therapy (ERT) for patients suffering from GM1 Gangliosidosis by applying a novel ERT enzyme-lectin fusion delivery strategy developed at BioStrategies LC and by exploiting safety, supply, and cost advantages of a plant-based ERT protein bio-manufacturing system. GM1 Gangliosidosis is a rare lysosomal disease affecting less than 200,000 people in the U.S. It is caused by a defect in the gene encoding the enzyme ?-galactosidase and is characterized by progressive degeneration of normal childhood development especially in brain function leading to death at an early age. Current treatment options are limited to management of disease symptoms and development of an effective ERT drug has been hindered by challenges of delivering these drugs across the blood brain barrier to the brain and central nervous system. This research project is a collaboration between BioStrategies LC, a company focused on doing innovative research in lysosomal disease ERT development, and St. Jude Children?s Research Hospital, an international center for GM1 Gangliosidosis research. This SBIR Phase II is designed to lead to an effective ERT treatment for GM1 Gangliosidosis patients, a patient population with desperate need for new therapeutic options. In Phase I we met project goals by showing that a plant-produced ERT consisting of a fusion between human ?-gal and the plant RTB lectin could be delivered into lysosomes of human disease cells where it reduced the pathogenic levels of GM1 substrate to normal. Follow up animal studies in the GM1 disease mouse model showed that this ERT complex was effective in delivering active enzyme to tissues of both visceral organs and the CNS producing a significant reduction in the high levels of GM1 enzyme substrate associated with the GM1 disease phenotype. These results raise the hope that this novel plant lectin-ERT fusion cell delivery technology could lead to a general paradigm shift for ERT-based treatment approaches in which ERTs could be used to effectively treat diseases that significantly affect the central nervous system. Based on our successful Phase I outcomes, Phase II will focus on detailed analyses confirming disease correction within the CNS and visceral organs of GM1 gangliosidosis mice, product scale-up and characterization to support further preclinical assessments and follow-on long-term animal studies on pharmacodynamics, dosing/administration parameters, and amelioration of disease manifestations with larger cohort sizes and gender representation consistent with Rigor and Reproducibility guidance. These studies will support our goal of gaining sufficient data to support a successful application to FDA for IND approval.
